Day: February 16, 2021

BOISE, Idaho, Feb. 16, 2021 (GLOBE NEWSWIRE) — Micron Technology, Inc. (Nasdaq: MU), an industry leader in innovative memory and storage solutions, today announced the appointment of Linnie Haynesworth to its board of directors. Haynesworth has more than 30 years of experience in technology, including aerospace and cybersecurity.“Linnie’s extensive expertise in complex system development, technology integration and risk management makes her a valuable addition to our board,” said Micron President and CEO Sanjay Mehrotra. “She also brings deep insights on cybersecurity that will provide fresh perspective as we further advance Micron’s technology leadership and deliver trusted solutions to address the growing data economy.”“Linnie has a wealth of knowledge that stems from leading billion-dollar business divisions, driving significant...

EMERYVILLE, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) — NMI Holdings, Inc. (Nasdaq: NMIH) today reported net income of $48.3 million, or $0.56 per diluted share, for the fourth quarter ended December 31, 2020, which compares to $38.2 million, or $0.45 per diluted share, in the third quarter ended September 30, 2020 and $50.2 million, or $0.71 per diluted share, in the fourth quarter ended December 31, 2019. Adjusted net income for the quarter was $50.8 million or $0.59 per diluted share, which compares to $40.4 million or $0.47 per diluted share in the third quarter ended September 30, 2020 and $52.6 million or $0.75 per diluted share in the fourth quarter ended December 31, 2019.Net income for the full year ended December 31, 2020 was $171.6 million or $2.13 per diluted share, which compares to $172.0 million or $2.47 per diluted...

First Investigational New Drug (IND) application cleared for NX-2127 in patients with relapsed and refractory B-cell malignanciesThree additional wholly owned programs expected to enter clinical trials in 2021Expanded Sanofi collaboration resulting in option exercise payment of $22 millionYear-end cash and investments totaling $372 millionSAN FRANCISCO, Feb. 16, 2021 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today reported financial results for the fourth quarter and fiscal year ended November 30, 2020 and provided a corporate update.“We begin 2021 with a positive notification from the FDA that our first Phase 1 clinical trial of NX-2127 may proceed in patients with B cell malignancies, including chronic lymphocytic leukemia,” said Arthur...

ALHAMBRA, CA, Feb. 16, 2021 (GLOBE NEWSWIRE) — EMCORE Corporation (Nasdaq: EMKR) today announced the closing of its underwritten public offering of 6,655,093 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 868,056 additional shares of common stock, at a public offering price of $5.40 per share. All of the shares in the offering were sold by EMCORE. The gross proceeds to EMCORE from the offering, before deducting the underwriting discounts and commissions and other offering expenses, were approximately $35.9 million.Cowen is acting as book-running manager and Craig-Hallum is acting as co-manager for the offering.The shares of common stock in the public offering were issued by EMCORE pursuant to a shelf registration statement (File No. 333-235818) previously filed with, and declared...

AUSTIN, Texas, Feb. 16, 2021 (GLOBE NEWSWIRE) — Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced the appointment of An van Es-Johansson, M.D., to its Board of Directors, effective immediately, where she will serve as a member of the Nominating and Governance Committee. Dr. van Es-Johansson brings over 30 years of experience in executive and clinical development roles in the pharmaceutical industry. Dr. van Es-Johansson will succeed Emmett Cunningham who is resigning his Board position to focus on other professional obligations in his managerial role at Blackstone Life Sciences.“We are excited to welcome Dr. An van Es-Johansson to our Board,” said Rick Hawkins, CEO, President and Chairman. “Dr. van Es-Johansson’s clinical and corporate experience focused...

– More than 20 patients have been dosed with CTX001™ across CLIMB-Thal-111 and CLIMB-SCD-121 to date; completion of enrollment in both trials is expected in 2021 –– The first patient treated in the CLIMB-Thal-111 trial completed two years of follow-up and has enrolled in the long-term follow-up trial, CTX001-131 –– Additional data from CTX110™ trial expected to report in 2021, along with top-line data from CTX120™ and CTX130™ –ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the fourth quarter and full year ended December 31, 2020.“2020 was a pivotal year in the growth of CRISPR Therapeutics. Data...

REDWOOD CITY, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) — Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the fourth quarter and full year of 2020 after the close of trading on Tuesday, March 2, 2021. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.Investors interested in listening to the conference call may do so by dialing (833) 614-1518 for domestic callers or (270) 823-1072 for international callers, followed by Conference ID: 6144267. A live and archived webcast of the event will be available on the “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.About Pulmonx CorporationPulmonx Corporation (NASDAQ: LUNG) is...

BOSTON, Feb. 16, 2021 (GLOBE NEWSWIRE) — Ziopharm Oncology, Inc. (the “Company”) (Nasdaq: ZIOP), today announced the Company will host a conference call and webcast to discuss financial results for the fourth quarter and full year 2020 on Thursday, February 25, 2021 at 4:30pm EDT.The live call can be accessed by dialing 1-877-451-6152 (U.S. and Canada) or 1-201-389-0879 (International). The passcode for the conference call is 13715482. The live webcast may be accessed using the link here, or by visiting the “Investors” section of the Ziopharm website at www.ziopharm.com. The call will be recorded and available for replay on the Company’s website for approximately 90 days after the call.Additionally, the Company announced today that management will host a virtual R&D Day on Thursday, March 11, 2021 at 11:00am EDT. Details for...

Not for distribution to United States newswire services or for dissemination in the United States.VANCOUVER, British Columbia, Feb. 16, 2021 (GLOBE NEWSWIRE) — ValOre Metals Corporation. (“ValOre”) (TSX-V: VO) today announced the intent to increase the size of the previously announced non-brokered private placement on January 29, 2021 from C$3,600,000 to C$8,330,000. The Company will issue up to 27,766,666 units for total gross proceeds of up to C$8,330,000 (“Private Placement”).Each unit will be issued at a price of C$0.30 and will consist of one common share of ValOre and one half of one common share purchase warrant (each, a “Unit”). Each whole warrant will be exercisable to acquire one common share of ValOre at an exercise price of C$0.45 for 24 months from the date of the closing of the Private Placement.The closing of the Private...

Los Angeles, CA, Feb. 16, 2021 (GLOBE NEWSWIRE) — Los Angeles, CA, February 16, 2021 (GLOBE NEWSWIRE) — KRONOS ADVANCED TECHNOLOGIES, INC. (OTC MARKETS: KNOS) (“KNOS” or the “Company”), product development and production company that has significantly changed the way air is moved, filtered and sterilized announced today the results in testing data conducted by an independent government-compliant, biosafety biology laboratory at Democritus University of Thrace which is ranked in the top 10 universities in Greece, European Union.The test results established a 99.02% kill rate (airborne disinfection reduction rate) of live airborne SARS-CoV-2 virus in just 30 seconds, within a six cubic feet test chamber, with Model 5 (X5) patented air purification based on Kronos CORE Technology.Once the Company applies...